Precigen Inc PGEN

NAS: PGEN | ISIN: US74017N1054   1/05/2025
1,550 USD (-0,64%)
(-0,64%)   1/05/2025

16 april 2025 · Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th · Persbericht

19 maart 2025 · Precigen Reports Full Year 2024 Financial Results and Business Updates · Persbericht

13 maart 2025 · Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th · Persbericht

14 augustus 2024 · Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates · Persbericht

9 augustus 2024 · Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th · Persbericht

8 augustus 2024 · Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock · Persbericht

6 augustus 2024 · Precigen Announces Proposed $30 Million Public Offering of Common Stock · Persbericht

6 augustus 2024 · Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch · Persbericht

23 juli 2024 · Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch · Persbericht

3 juni 2024 · Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response · Persbericht

23 mei 2024 · Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting · Persbericht

14 mei 2024 · Precigen Reports First Quarter 2024 Financial Results and Business Updates · Persbericht

8 mei 2024 · Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting · Persbericht

24 april 2024 · Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting · Persbericht

24 april 2024 · Actym Therapeutics Appoints Thomas Smart as CEO · Persbericht

28 maart 2024 · Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th · Persbericht

19 maart 2024 · Precigen Reports Full Year 2023 Financial Results and Business Updates · Persbericht

12 maart 2024 · Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis · Persbericht

5 maart 2024 · Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th · Persbericht

6 februari 2024 · Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference · Persbericht

Mijn selecties